Peripheral arterial disease (PAD) is a common manifestation of stenoses and occlusions of the arteries of the lower extremities. Clinically, PAD is an important effect on functional ability, and quality of life because symptomatic patients are typically able to walk less than one to three blocks before rest is required.The double product break point (DPBP), also defined as the oxygen consumption at which the first portion of nonlinear increase in rate pressure product (systolic blood pressure X heart rate) begins has been identified to determine the anaerobic threshold during exercise test. The purpose of this study was to determine whether the DPBP could be detected in patients with PAD during a symptom-limited GXT on the motor-driven treadmill. Six male subjects (68.2 ± 6.5 yrs) with history of diagnosis of PAD participated in this study. Double product (DP) was assessed every 15 seconds during the test via the Kyokko Bussan CM-4001 automated blood pressure unit. The DPBP and VT were determined visually by three blinded observers. The mean values of Peak V02 and maximal heart rate were 19.4 ± 5.8 (ml/kg/min) and 130 ± 13 (bpm), respectively. In 4 of the six exercise tests in the present study, the DPBP and the VT were determined. The mean V02 at the DPBP and the VT were 15.7 ± 2.6 ml/kg/min and 14.2 ± 0.6 ml/kg/min, corresponding to 73 ± 7.2 and 74.5 ± 5.4 % respectively. In 3 of the six exercise tests both of the DPBP and VT were determined. The Mean V02 at the DPBP and VT were 14.6 ± 1.8 and 14.3 ± 0.7, respectively. The difference of the mean VO2 at the VT and DPBP was -.0.33 ml/kg/min.In conclusion, the results of the present study suggest that the DPBP can be identified and used as a useful marker to determine the functional performance in PAD patients. Walking time or distance measurement depends on the patient's perception of the pain. Thus, this study provides an objective way to appraise the functional performance and therapeutic results obtained from the exercise training in PAD patients, and provides a reference for exercise prescription for this population. / School of Physical Education

Previous research has reported positive associations between anger, perceived stress and blood pressure. These associations have largely been based on cross-sectional data and a small number of longitudinal works. Using a prospective longitudinal cohort design, this study more directly tested the relationships between anger, perceived stress and blood pressure by using a psychological therapeutic intervention (mindfulness-based stress reduction) to manipulate anger and perceived stress. Anger and perceived stress were in turn evaluated for association with blood pressure. Despite improvements in psychosocial functioning and reductions in blood pressure, findings from this study failed to demonstrate an association between change in anger or perceived stress with change in daytime or 24-hour ambulatory blood pressure. A model where these variables interact indirectly via stress coping mechanisms or health behaviours may be the linking mechanism in this study. Results from this thesis have contributed evidence to a divided field dominated by cross-sectional research.

Previous research has reported positive associations between anger, perceived stress and blood pressure. These associations have largely been based on cross-sectional data and a small number of longitudinal works. Using a prospective longitudinal cohort design, this study more directly tested the relationships between anger, perceived stress and blood pressure by using a psychological therapeutic intervention (mindfulness-based stress reduction) to manipulate anger and perceived stress. Anger and perceived stress were in turn evaluated for association with blood pressure. Despite improvements in psychosocial functioning and reductions in blood pressure, findings from this study failed to demonstrate an association between change in anger or perceived stress with change in daytime or 24-hour ambulatory blood pressure. A model where these variables interact indirectly via stress coping mechanisms or health behaviours may be the linking mechanism in this study. Results from this thesis have contributed evidence to a divided field dominated by cross-sectional research.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.

Thesis (Ph. D.)--University of Washington, 1997. / Vita. Includes bibliographical references (leaves [216]-217).

Objetivo: Investigar o efeito de se distinguir a pressão arterial noturna da pressão arterial no sono pelo registro simultâneo da monitorização ambulatorial da pressão arterial e da polissonografia. Métodos: Recrutaram-se 36 pacientes, 29 homens e 7 mulheres, com suspeita de síndrome das apnéias e hipopnéias obstrutivas do sono (SAHOS), encaminhados à clínica do sono para investigação diagnóstica e que concordaram usar o monitor ambulatorial de pressão arterial (MAPA) Spacelabs 90207 ABP durante a polissonografia (PSG). A média de idade dos indivíduos era 45 ± 11 anos; o índice de massa corporal (IMC), 30,8 ± 5,4 Kg/m2; o índice de apnéias e hipopnéias, 35 ± 29 AH/h. Um microfone acoplado ao monitor ambulatorial de PA registrou os sons característicos de sua atividade em um canal da polissonografia e permitiu determinar, de modo eletrográfico, se a PA foi medida em sono (e-sono) ou vigília (e-vigília).Resultados: Os pacientes encontravam-se dormindo durante (média+DP) 61+24% (variando de 0 a 100%), das 14+1 medidas de pressão arterial durante a noite. Leituras de pressão sistólica e diastólica na MAPA foram significativamente maiores durante o evigília (121 + 12 / 73 + 9 mm Hg) que durante o total do período noturno (119 + 11 / 70 + 8 mmHg) e e-sono (116 + 13 / 68 + 9 mm Hg). Baseado nas medidas do período noturno, 22 pacientes (61%) tinham hipertensão noturna; baseado nas medidas do período de e-sono, 12 pacientes tinham hipertensão noturna (33%; qui-quadrado= 5,54; p= 0,018). Um modelo de regressão linear múltipla mostrou que a percentagem de medidas feitas durante o e-sono foi a única variável que explicou significantemente a diferença entre os valores de PA noturna e PA em e-sono, controlando para gênero, idade, IMC, IAH, e SaO2 mínima. Conclusão: Durante a MAPA as leituras de PA noturnas são mais altas que as leituras durante e-sono. / Objective: Investigate the effect of distinguishing nighttime and sleep on nocturnal blood pressure results in ambulatory blood pressure monitoring (ABPM). Methods: We recruited 36 patients, 28 male, with suspected OSAHS attending a sleep clinic for diagnostic polysomnography (PSG) and who agreed to wear a Spacelabs 90207 ABP monitor during PSG. Their mean age was 45±11 years; body mass index (BMI), 30.8±5.4 kg/m2; apnea-hypopnea index (AHI), 35±29 AH/h; 13 had history of hypertension. A microphone attached to the ABP monitor recorded its sounds in the polygraph and allowed to classify each ABPM measurement as being made in electrographically-determined wake (e-wake) or sleep state (e-sleep). Results: Patients were asleep during (mean±SD) 61±24% (range 0 to 100%) of the 14±1 nighttime BP measurements. Systolic and diastolic ABPM readings were significantly higher during e-wake (121±12 / 73±9 mm Hg) than during total nighttime (119±11/70±8 m Hg) and e-sleep (116±13 / 68±9 mm Hg). Based on nighttime measurements 22 patients (61%) had nocturnal hypertension. Based on measurements made during e-sleep, nocturnal hypertension was diagnosed in 12 patients (33%; chisquare= 5.54; p= 0.018). A multiple linear regression model showed that the percentage of measurements made in e-sleep was the only variable that significantly explained the difference between nighttime and e-sleep BP figures, when controlling for gender, age, BMI, AHI, and lowest SaO2. Conclusion: During ABPM, nighttime BP readings are higher than during e-sleep and this changes dipping and nocturnal hypertension classification.

abstract: Intracranial pressure is an important parameter to monitor, and elevated intracranial pressure can be life threatening. Elevated intracranial pressure is indicative of distress in the brain attributed by conditions such as aneurysm, traumatic brain injury, brain tumor, hydrocephalus, stroke, or meningitis. Electrocorticography (ECoG) recordings are invaluable in understanding epilepsy and detecting seizure zones. However, ECoG electrodes cause a foreign body mass effect, swelling, and pneumocephaly, which results in elevation of intracranial pressure (ICP). Thus, the aim of this work is to design an intracranial pressure monitoring system that could augment ECoG electrodes. A minimally invasive, low-cost epidural intracranial pressure monitoring system is developed for this purpose, using a commercial pressure transducer available for biomedical applications. The system is composed of a pressure transducer, sensing cup, electronics, and data acquisition system. The pressure transducer is a microelectromechanical system (MEMS)-based die that works on piezoresistive phenomenon with dielectric isolation for direct contact with fluids. The developed system was bench tested and verified in an animal model to confirm the efficacy of the system for intracranial pressure monitoring. The system has a 0.1 mmHg accuracy and a 2% error for the 0-10 mmHg range, with resolution of 0.01 mmHg. This system serves as a minimally invasive (2 mm burr hole) epidural ICP monitor, which could augment existing ECoG electrode arrays, to simultaneously measure intracranial pressure along with the neural signals. This device could also be employed with brain implants that causes elevation in ICP due to tissue - implant interaction often leading to edema. This research explores the concept and feasibility for integrating the sensing component directly on to the ECoG electrode arrays. / Dissertation/Thesis / Masters Thesis Bioengineering 2015

A taxa de controle da hipertensão arterial permanece subótima apesar dos amplos e intensos programas institucionais e o número das novas medicações. A combinação de drogas de diferentes mecanismos de ação vem se tornando uma alternativa para aumentar a redução na pressão arterial (PA) e aumentar seu controle, aumentar aderência ao tratamento e reduzir os eventos adversos. Um estudo fatorial 4X4 foi desenhado para determinar a eficácia e a segurança de telmisartana (T) mais anlodipino (A) em pacientes hipertensos estágios I e II. Pacientes hipertensos adultos (N=1461) estágios I e II (pressão arterial basal 153,212,1 &#8260;101,74,3 mm Hg) foram randomizados para 1 de 16 grupos de tratamento com T 0, 20, 40, 80 mg e A 0, 2.5, 5, 10 mg por oito semanas. A maior redução na média das pressões sistólica e diastólica foram observadas com T 80 mg mais A10 mg (- 26,4 &#8260;20,1 mm Hg; p<0,05 comparados com as monoterapias). A taxa de controle da PA foi também maior no grupo T 80mg mais A 10mg (76,5% [controle total] e 85,3% [controle da PA diastólica ]), e taxa de controle da PA >90% com esta combinação. O edema periférico maleolar foi o evento adverso mais frequente e ocorreu no grupo A 10mg (17,8%), porém, esta taxa foi marcadamente menor quando A foi usada associada com T: 11,4% (T20+A10), 6,2% (T40+ A10), e 11,3% (T80+A10). Um subestudo utilizando a monitorização ambulatorial da pressão arterial (MAPA) foi realizado na fase basal e após oito semanas de tratamento. A maior redução média das pressões nas 24 horas a partir do período basal foi registrada para a combinação de telmisartana 80 mg e anlodipino 10 mg e encontrou-se queda de 22,4/14,6 mmHg, de 11,9/6,9 mmHg para anlodipino 10 mg monoterapia e de 11,0/6,9 mmHg para telmisartana 80 mg (p< 0,001). Além disso, resultados relevantes foram também constatados numa análise post hoc de subgrupos incluindo idosos, obesos, diabéticos tipo 2 e hipertensão sistólica. A resposta anti-hipertensiva da combinação foi semelhante, independente de qualquer característica de cada subgrupo. Estes dados demonstram que telmisartana e anlodipino em combinação oferecem substancial redução e controle nas 24 horas superior às respectivas monoterapias em hipertensos estágios I e II. / The rate of control of hypertension remains suboptimal despite widespread educational programs and the increasing number of novel medications. The combination of drugs with different mechanism of action has become an alternative to improve blood pressure reduction and control, enhance adherence to the treatment and reduce adverse events. This randomized 4X4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure (BP) 153.212.1 &#8260;101.74.3 mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20, 40, 80 mg and A 0, 2.5, 5, 10 mg for 8 weeks. The greatest leastsquare mean systolic &#8260; diastolic BP reductions were observed with T80 mg plus A10 mg (- 26.4 &#8260;20.1 mm Hg; P<.05 compared with both monotherapies). BP control was also greater in the T80-mg plus A10-mg group (76.5% [overall control] and 85.3% [diastolic BP control]), and BP response rates >90% with this combination. Peripheral edema was most common in the A10-mg group (17.8%); however, this rate was notably lower when A was used in combination with T: 11.4% (T20 &#8260; A10), 6.2% (T40 &#8260; A10), and 11.3% (T80 &#8260; A10). Ambulatory BP monitoring (ABPM) was performed, at baseline and after 8 weeks of treatment; the endpoints of interest were the changes from baseline in 24-hour systolic and diastolic BP. Mean reductions from baseline in 24-hour BP for the combination of the highest doses of telmisartan 80 mg and amlodipine 10 mg were -22.4/-14.6 mmHg versus -11.9/-6.9 mmHg for amlodipine 10 mg and -11.0/-6.9 mmHg for telmisartan 80 mg (p< 0.001 for each comparison. This study also presents most of the relevant results in hypertensive patients and a post hoc analysis of subgroups including elderly, diabetics type 2, systolic hypertension and obese patients. These findings demonstrate that telmisartan and amlodipine in combination provide substantial 24 hour BP efficacy that is superior to either monotherapy in patients with stages 1 and 2 hypertension.

Objetivo: Investigar o efeito de se distinguir a pressão arterial noturna da pressão arterial no sono pelo registro simultâneo da monitorização ambulatorial da pressão arterial e da polissonografia. Métodos: Recrutaram-se 36 pacientes, 29 homens e 7 mulheres, com suspeita de síndrome das apnéias e hipopnéias obstrutivas do sono (SAHOS), encaminhados à clínica do sono para investigação diagnóstica e que concordaram usar o monitor ambulatorial de pressão arterial (MAPA) Spacelabs 90207 ABP durante a polissonografia (PSG). A média de idade dos indivíduos era 45 ± 11 anos; o índice de massa corporal (IMC), 30,8 ± 5,4 Kg/m2; o índice de apnéias e hipopnéias, 35 ± 29 AH/h. Um microfone acoplado ao monitor ambulatorial de PA registrou os sons característicos de sua atividade em um canal da polissonografia e permitiu determinar, de modo eletrográfico, se a PA foi medida em sono (e-sono) ou vigília (e-vigília).Resultados: Os pacientes encontravam-se dormindo durante (média+DP) 61+24% (variando de 0 a 100%), das 14+1 medidas de pressão arterial durante a noite. Leituras de pressão sistólica e diastólica na MAPA foram significativamente maiores durante o evigília (121 + 12 / 73 + 9 mm Hg) que durante o total do período noturno (119 + 11 / 70 + 8 mmHg) e e-sono (116 + 13 / 68 + 9 mm Hg). Baseado nas medidas do período noturno, 22 pacientes (61%) tinham hipertensão noturna; baseado nas medidas do período de e-sono, 12 pacientes tinham hipertensão noturna (33%; qui-quadrado= 5,54; p= 0,018). Um modelo de regressão linear múltipla mostrou que a percentagem de medidas feitas durante o e-sono foi a única variável que explicou significantemente a diferença entre os valores de PA noturna e PA em e-sono, controlando para gênero, idade, IMC, IAH, e SaO2 mínima. Conclusão: Durante a MAPA as leituras de PA noturnas são mais altas que as leituras durante e-sono. / Objective: Investigate the effect of distinguishing nighttime and sleep on nocturnal blood pressure results in ambulatory blood pressure monitoring (ABPM). Methods: We recruited 36 patients, 28 male, with suspected OSAHS attending a sleep clinic for diagnostic polysomnography (PSG) and who agreed to wear a Spacelabs 90207 ABP monitor during PSG. Their mean age was 45±11 years; body mass index (BMI), 30.8±5.4 kg/m2; apnea-hypopnea index (AHI), 35±29 AH/h; 13 had history of hypertension. A microphone attached to the ABP monitor recorded its sounds in the polygraph and allowed to classify each ABPM measurement as being made in electrographically-determined wake (e-wake) or sleep state (e-sleep). Results: Patients were asleep during (mean±SD) 61±24% (range 0 to 100%) of the 14±1 nighttime BP measurements. Systolic and diastolic ABPM readings were significantly higher during e-wake (121±12 / 73±9 mm Hg) than during total nighttime (119±11/70±8 m Hg) and e-sleep (116±13 / 68±9 mm Hg). Based on nighttime measurements 22 patients (61%) had nocturnal hypertension. Based on measurements made during e-sleep, nocturnal hypertension was diagnosed in 12 patients (33%; chisquare= 5.54; p= 0.018). A multiple linear regression model showed that the percentage of measurements made in e-sleep was the only variable that significantly explained the difference between nighttime and e-sleep BP figures, when controlling for gender, age, BMI, AHI, and lowest SaO2. Conclusion: During ABPM, nighttime BP readings are higher than during e-sleep and this changes dipping and nocturnal hypertension classification.

Objetivo: Investigar o efeito de se distinguir a pressão arterial noturna da pressão arterial no sono pelo registro simultâneo da monitorização ambulatorial da pressão arterial e da polissonografia. Métodos: Recrutaram-se 36 pacientes, 29 homens e 7 mulheres, com suspeita de síndrome das apnéias e hipopnéias obstrutivas do sono (SAHOS), encaminhados à clínica do sono para investigação diagnóstica e que concordaram usar o monitor ambulatorial de pressão arterial (MAPA) Spacelabs 90207 ABP durante a polissonografia (PSG). A média de idade dos indivíduos era 45 ± 11 anos; o índice de massa corporal (IMC), 30,8 ± 5,4 Kg/m2; o índice de apnéias e hipopnéias, 35 ± 29 AH/h. Um microfone acoplado ao monitor ambulatorial de PA registrou os sons característicos de sua atividade em um canal da polissonografia e permitiu determinar, de modo eletrográfico, se a PA foi medida em sono (e-sono) ou vigília (e-vigília).Resultados: Os pacientes encontravam-se dormindo durante (média+DP) 61+24% (variando de 0 a 100%), das 14+1 medidas de pressão arterial durante a noite. Leituras de pressão sistólica e diastólica na MAPA foram significativamente maiores durante o evigília (121 + 12 / 73 + 9 mm Hg) que durante o total do período noturno (119 + 11 / 70 + 8 mmHg) e e-sono (116 + 13 / 68 + 9 mm Hg). Baseado nas medidas do período noturno, 22 pacientes (61%) tinham hipertensão noturna; baseado nas medidas do período de e-sono, 12 pacientes tinham hipertensão noturna (33%; qui-quadrado= 5,54; p= 0,018). Um modelo de regressão linear múltipla mostrou que a percentagem de medidas feitas durante o e-sono foi a única variável que explicou significantemente a diferença entre os valores de PA noturna e PA em e-sono, controlando para gênero, idade, IMC, IAH, e SaO2 mínima. Conclusão: Durante a MAPA as leituras de PA noturnas são mais altas que as leituras durante e-sono. / Objective: Investigate the effect of distinguishing nighttime and sleep on nocturnal blood pressure results in ambulatory blood pressure monitoring (ABPM). Methods: We recruited 36 patients, 28 male, with suspected OSAHS attending a sleep clinic for diagnostic polysomnography (PSG) and who agreed to wear a Spacelabs 90207 ABP monitor during PSG. Their mean age was 45±11 years; body mass index (BMI), 30.8±5.4 kg/m2; apnea-hypopnea index (AHI), 35±29 AH/h; 13 had history of hypertension. A microphone attached to the ABP monitor recorded its sounds in the polygraph and allowed to classify each ABPM measurement as being made in electrographically-determined wake (e-wake) or sleep state (e-sleep). Results: Patients were asleep during (mean±SD) 61±24% (range 0 to 100%) of the 14±1 nighttime BP measurements. Systolic and diastolic ABPM readings were significantly higher during e-wake (121±12 / 73±9 mm Hg) than during total nighttime (119±11/70±8 m Hg) and e-sleep (116±13 / 68±9 mm Hg). Based on nighttime measurements 22 patients (61%) had nocturnal hypertension. Based on measurements made during e-sleep, nocturnal hypertension was diagnosed in 12 patients (33%; chisquare= 5.54; p= 0.018). A multiple linear regression model showed that the percentage of measurements made in e-sleep was the only variable that significantly explained the difference between nighttime and e-sleep BP figures, when controlling for gender, age, BMI, AHI, and lowest SaO2. Conclusion: During ABPM, nighttime BP readings are higher than during e-sleep and this changes dipping and nocturnal hypertension classification.